| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 22.00K | 95.00K | 156.00K | 114.09M | 0.00 |
| Gross Profit | -12.64M | 22.00K | -242.82M | -14.14M | 103.64M | -11.54M |
| EBITDA | -232.47M | -243.33M | -313.07M | -321.24M | -169.74M | -238.68M |
| Net Income | -236.91M | -257.59M | -327.26M | -340.41M | -182.05M | -250.22M |
Balance Sheet | ||||||
| Total Assets | 470.59M | 548.71M | 642.84M | 817.08M | 1.05B | 1.23B |
| Cash, Cash Equivalents and Short-Term Investments | 273.12M | 292.48M | 448.70M | 517.32M | 457.30M | 827.91M |
| Total Debt | 79.24M | 90.76M | 95.12M | 101.12M | 73.13M | 53.78M |
| Total Liabilities | 126.03M | 126.53M | 130.60M | 154.70M | 122.23M | 148.21M |
| Stockholders Equity | 344.56M | 422.18M | 512.23M | 665.87M | 916.41M | 1.08B |
Cash Flow | ||||||
| Free Cash Flow | -173.60M | -200.99M | -239.25M | -225.71M | -206.26M | -181.05M |
| Operating Cash Flow | -172.77M | -200.30M | -237.73M | -220.52M | -184.81M | -115.09M |
| Investing Cash Flow | 28.95M | 75.69M | 163.29M | 106.16M | 163.66M | -505.12M |
| Financing Cash Flow | 25.48M | 116.67M | 95.69M | 2.95M | 11.96M | 633.59M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $270.75M | 8.37 | 48.34% | ― | ― | ― | |
| ― | $279.57M | -1.13 | -55.12% | ― | -100.00% | 30.91% | |
| ― | $334.19M | ― | ― | ― | -100.00% | 72.45% | |
| ― | $230.08M | -3.28 | ― | ― | -31.30% | 36.26% | |
| ― | $270.54M | -1.73 | -85.21% | ― | ― | 38.94% | |
| ― | $280.17M | ― | -89.37% | ― | ― | 9.84% |
Allogene Therapeutics is currently conducting a study titled ‘A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma.’ The study aims to evaluate the effectiveness and safety of cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, in patients with large B-cell lymphoma (LBCL) who have minimal residual disease (MRD) after initial therapy. This research is significant as it explores a potential new treatment avenue for patients who have shown a response to first-line therapy but still harbor MRD.
Allogene Therapeutics’ recent earnings call conveyed a cautiously optimistic sentiment. While the company reported significant advancements in its clinical trials and maintained a stable financial position, the announcement of a Grade 5 event in the ALPHA3 study raised safety concerns. This mix of positive developments and safety challenges paints a promising yet cautious outlook for the company.
Allogene Therapeutics faces significant risks due to evolving political, trade, and regulatory developments, particularly following the U.S. government’s announcement of new tariffs in 2025. These tariffs, which include a baseline of 10-15% and country-specific rates as high as 25-39%, could adversely affect pharmaceutical imports, impacting the company’s financial condition and operations. The dynamic and unpredictable nature of these policy changes, coupled with potential investigations into national security risks associated with foreign-manufactured pharmaceutical ingredients, adds further uncertainty. As Allogene Therapeutics relies on global third-party suppliers for raw materials, increased tariffs may lead to higher research and development expenses, posing a material risk to their business prospects.
Allogene Therapeutics is a clinical-stage biotechnology company based in South San Francisco, specializing in the development of allogeneic CAR T cell therapies for cancer and autoimmune diseases. The company is known for its innovative ‘off-the-shelf’ cell therapy products aimed at providing scalable and accessible treatment options.
On August 1, 2025, Allogene Therapeutics announced the selection of standard fludarabine and cyclophosphamide as the lymphodepletion regimen for its ALPHA3 study, following a Grade 5 adverse event linked to ALLO-647. The decision to close the arm testing FC plus ALLO-647 was made after consultation with the FDA and the DSMB due to severe viral infections attributed to immunosuppression from ALLO-647. The amended ALPHA3 trial will now proceed with two arms, comparing cema-cel after standard FC lymphodepletion to observation, with the next milestone being a futility analysis expected in the first half of 2026. The company will focus on advancing its AlloCAR T product candidates using the Dagger® Platform Technology, which aims to reduce the need for standard lymphodepletion.
The most recent analyst rating on (ALLO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Allogene Therapeutics stock, see the ALLO Stock Forecast page.